Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Jay Hancock
Jay Hancock was a senior correspondent for ϳԹ News until he retired in Feburary 2022.
Showing 41 - 60 of 265
-
-
False Lead: Senator’s Offer To Help Patient Import Cheap Insulin Goes Nowhere
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
By Jay Hancock -
Trump Administration Salutes Parade Of Generic Drug Approvals, But Hundreds Aren’t For Sale
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
By Sydney Lupkin and Jay Hancock -
Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
By Jay Hancock -
Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
By Jay Hancock and Sydney Lupkin -
Chronically Ill, Traumatically Billed: The $123,000 Medicine For MS
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
By Jay Hancock -
High-Deductible Health Plans Fall From Grace In Employer-Based Coverage
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
By Jay Hancock -
Putting Oversized Health Care Costs Upfront — On T-Shirts
The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
By Jay Hancock -
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
By Emily Kopp and Jay Hancock -
States Looking To Tax Opioids Pin Hopes On November Elections
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
By Jay Hancock and Shefali Luthra -
As An Investor In Biotech Stock, Republican Chris Collins May Have Overshared
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
-
Drug Trade Group Quietly Spends ‘Dark Money’ To Sway Policy And Voters
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
By Jay Hancock -
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
By Jay Hancock and Sarah Jane Tribble -
Administration Eases Way For Small Businesses To Buy Insurance In Bulk
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.”
By Jay Hancock and Julie Appleby -
Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
By Jay Hancock -
As Proton Centers Struggle, A Sign Of A Health Care Bubble?
Companies pushed proton machines and counted on advertising, doctors and insurers to ensure a steady business treating cancer. But the dollars haven’t flowed in as expected.
By Jay Hancock -
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
By Jay Hancock and Elizabeth Lucas -
Paying Hospitals To Keep People Out Of Hospitals? It Works In Maryland.
The state’s ambitious payment overhaul has begun to demonstrate savings and a change in culture, say new reports.
By Jay Hancock -
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
By Jay Hancock and Shefali Luthra -
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
By Jay Hancock
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: